NuVasive Sales Slide on COVID and Supply Pressures

NuVasive reported 3Q21 orthopedic sales of $270.8 million, -8.3% vs. 3Q21 and -6.9% vs. 3Q19. Due to the impact of COVID and hospital staffing shortages on the remainder of the year, the company lowered its 2021 sales guidance to the range of $1.132 billion to $1.142 billion, representing a growth mid-point of +8.2% over 2020.

NuVasive...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

ME

Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.



Contact Us

0